List view / Grid view
16 September 2015 | By Victoria White
The designation is based on results of CheckMate -025, a Phase 3 study that evaluated the survival of patients with previously treated advanced or metastatic clear-cell RCC versus everolimus...
16 September 2015 | By Victoria White
Results from a new study showed different perceptions of control among physicians and patients that may lead to suboptimal type 2 diabetes management...
16 September 2015 | By Bachem AG
Bachem Group increased its sales by about 15% to nearly 100 million CHF in the first half of 2015...
16 September 2015 | By Victoria White
Blue Latitude has been reappointed to provide Janssen with strategic support and creative marketing services for their brand teams in the EMEA region...
16 September 2015 | By Victoria White
Findings from the LIRA-LIXI trial have demonstrated a significantly greater reduction in blood sugar for liraglutide compared to lixisenatide in type 2 diabetes...
16 September 2015 | By Victoria White
Nuwiq is the first B-domain deleted recombinant Factor VIII derived from a human cell-line designed for the treatment of patients with haemophilia A...
16 September 2015 | By Victoria White
Moss-aGal, a recombinant form of human alpha galactosidase, is the world´s first moss-produced drug candidate...
15 September 2015 | By Victoria White
Data from secondary analyses of Phase III trials show Abasaglar (insulin glargine) demonstrated safety and efficacy outcomes similar to Lantus in diabetes...
15 September 2015 | By Victoria White
Data show that Tresiba U200 significantly lowers both rates of hypoglycaemia and mean fasting blood glucose compared to insulin glargine U100 in patients with type 2 diabetes...
15 September 2015 | By Victoria White
The addition of Cannabidiol (CBD)to the medication of patients who were only partially responsive to standard treatment produced significant improvements in outcome measures...
15 September 2015 | By Victoria White
Not only are Saxenda 'early responders' more likely to achieve greater weight loss, they are also more likely to experience greater improvements in cardiometabolic risk factors...
15 September 2015 | By Victoria White
Crucell Holland has been awarded $28.5 million from BARDA to help accelerate the development of its investigational Ebola prime-boost vaccine regimen...
15 September 2015 | By Victoria White
The agreement is in line with the Daiichi Sankyo R&D strategy to expand its portfolio in the prevention and treatment of thrombosis...
14 September 2015 | By Victoria White
The Phase 3 programme includes two replicate three-month efficacy studies and a single 12-month safety study...
14 September 2015 | By Victoria White
A supplemental New Drug Application (sNDA) for Imbruvica (ibrutinib) has been submitted to the US Food and Drug Administration (FDA) for front-line use in patients with chronic lymphocytic leukaemia (CLL).
